Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction.

Intern Med J · 2022 · PMC9796501 · PMID 35257458

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

Nevertheless, the loss of a single mechanism may not be significant, given the fact that the two therapies achieve their renoprotective effects through a range of distinct mechanisms.

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.